Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enVVeno MedicalNVNO +0.58%26 Cash Ratio is 11.39 as of Jun. 2026, which is 10% below its 10-year median of 12.65. GuruFocus rates NVNO with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 804 Medical Devices & Instruments companies, enVVeno Medical ranks better than 96.89% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
enVVeno Medical Cash Ratio Related Terms
enVVeno Medical Cash Ratio Historical Data
* Premium members only.
The historical data trend for enVVeno Medical's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, enVVeno Medical's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enVVeno Medical Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, enVVeno Medical's Cash Ratio distribution charts can be found below:
* The bar in red indicates where enVVeno Medical's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enVVeno Medical (NVNO) has a Cash Ratio of 11.39 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on enVVeno Medical and its competitors. This is 10% below median its historical median of 12.65. Over the past decade, enVVeno Medical's Cash Ratio has ranged from 0.01 to 51.79. According to the industry distribution chart, enVVeno Medical ranks #25 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 3.1%.
Is enVVeno Medical's Cash Ratio too high?
enVVeno Medical's current Cash Ratio of 11.39 is 10% below median its 10-year median of 12.65. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 51.79. The Medical Devices & Instruments industry median Cash Ratio is 0.96. enVVeno Medical's value of 11.39 is 1092.7% above this industry median. Based on the distribution chart, enVVeno Medical ranks #25 out of 804 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, enVVeno Medical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does enVVeno Medical's Cash Ratio compare to CODX and HSCS?
According to the Medical Devices & Instruments industry distribution chart, enVVeno Medical ranks #25 out of 804 companies for Cash Ratio. This places enVVeno Medical in the top 3% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.96. enVVeno Medical's value of 11.39 is 1092.7% above this benchmark. Historically, enVVeno Medical's own Cash Ratio has ranged from 0.01 to 51.79 over the past decade. While the company's 10-year median is 12.65 vs. the industry median of 0.96, enVVeno Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.96, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. enVVeno Medical's current Cash Ratio of 11.39 is 1092.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on enVVeno Medical and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. enVVeno Medical's current Cash Ratio is 11.39, which is 10% below median its own 10-year median of 12.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enVVeno Medical stock overvalued right now?
enVVeno Medical (NVNO) has a current Cash Ratio of 11.39. The current Cash Ratio is 11.39, which is 10% below median its 10-year median of 12.65 and 1092.7% above the Medical Devices & Instruments industry median of 0.96. enVVeno Medical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For enVVeno Medical (NVNO), the current Cash Ratio is 11.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
26GF Score
Get the complete analysis for NVNO
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVNO has been successfully added to your 
